Skip to content
Vial Announces Dosing of First Patient in Phase 1 Healthy Volunteer Trial
ABOUT US
ABOUT US
CAREERS
CONTACT US
PIPELINE
INHBE siRNA
IL-13 x TSLP
TMPRSS6
MYOSTATIN (GDF8)
α4β7 x IL-23
IL‑31 x IL‑4Rα
UPDATES
PARTNERSHIP
LICENSING
Back to Resources
Articles
January 9, 2026
Vial is geared up to attend the 44th Annual J.P. Morgan Healthcare Conference in San Francisco
More Resources
Contact Us
Comments
This field is for validation purposes and should be left unchanged.
Name
(Required)
First
Last
Work email
(Required)
Phone
Company
Which best describes you?
(Required)
Which best describes you?*
Sponsor (Clinical Stage)
Sponsor (Preclinical Stage - FIH trial within 6 months)
Sponsor (Preclinical Stage - FIH trial in 6+ months)
Clinic/Site
Other
Message
By submitting, you are agreeing to our
terms
and
privacy policy
Δ
Clear search querie
